PTGX Protagonist Therapeutics Inc.

18.91
+0.35  (2%)
Previous Close 18.56
Open 18.83
Price To book 6.71
Market Cap 387270427
Shares 20,479,663
Volume 11,525
Short Ratio 2.72
Av. Daily Volume 120,718

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171180931
  2. 8-K - Current report 171179510
  3. 8-K - Current report 171136682
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171136661
  5. 424B5 - Prospectus [Rule 424(b)(5)] 171133235

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b initiation announced January 17, 2017. Interim futility analysis early 2018 with top-line data due 2018.
PTG-100
Ulcerative colitis

Latest News

  1. Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 20, 2017
  2. Protagonist Therapeutics, Inc. – Value Analysis (NASDAQ:PTGX) : November 10, 2017
  3. Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200
  4. Protagonist Therapeutics posts 3Q loss
  5. Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
  6. Protagonist Therapeutics to Present at the Stifel 2017 Healthcare Conference
  7. Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
  8. Protagonist Therapeutics Prices Public Offering of Common Stock
  9. Protagonist Therapeutics Announces Proposed Public Offering of Common Stock
  10. Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
  11. /C O R R E C T I O N -- Protagonist Therapeutics, Inc./
  12. Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
  13. Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment
  14. Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights
  15. Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors
  16. A small biotech wants to disrupt billion-dollar injectable drug markets with a single pill
  17. Why Analysts Think Protagonist Therapeutics Could Still More Than Double After the News
  18. Protagonist Therapeutics Inks License Pact With Johnson & Johnson's Janssen
  19. Why Protagonist Therapeutics Shares Are Climbing

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171180931
  2. 8-K - Current report 171179510
  3. 8-K - Current report 171136682
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171136661
  5. 424B5 - Prospectus [Rule 424(b)(5)] 171133235
  6. EFFECT - Notice of Effectiveness 171125701
  7. CORRESP [Cover] - Correspondence
  8. CORRESP [Cover] - Correspondence
  9. UPLOAD [Cover] - SEC-generated letter
  10. S-3 - Registration statement under Securities Act of 1933 171066761